Ensayos clínicos

Inclusion Criteria:

- Participants diagnosed with chronic hypoparathyroidism, that is, hypoparathyroidism
with a duration of longer than 6 months, including:

1. Adult participants (greater than or equal to [>=] 18 years of age) who are
receiving for chronic hypoparathyroidism any of the following options: standard
therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.

2. Pediatric participants (less than [<] 18 years of age) who are receiving for
chronic hypoparathyroidism any of the following options: standard therapy,
standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.

Exclusion Criteria:

- Participants or legally acceptable representatives unable to provide informed consent.

- Participants using rhPTH(1-34) or who used rhPTH(1-34) for more than 2 years are
excluded. Participants who had been treated with rhPTH(1-34) within 3 months of
enrollment are also excluded as are participants currently using rhPTH(1-34).

FOR US SITES ONLY: Participants treated with rhPTH(1-84) prior to the US recall may use
rhPTH(1-34) only while rhPTH(1-84) is unavailable due to the recall.

- Participants currently enrolled in an interventional clinical study (whether or not
the study is related to hypoparathyroidism); note that this does not include
participants enrolled in other observational registries.

- History of hypoparathyroidism resulting from impaired responsiveness to PTH
(pseudohypoparathyroidism).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/30/22. Questions regarding updates should be directed to the study team contact.